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Abstract
Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom
proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPIb, α2β1, GPVI,
CLEC-2 and integrins αIIbβ3, αvβ3, α5β1 expressed on platelets, endothelial cells, phagocytes, tumor cells, thus
affecting cell-matrices and cell-cell interactions. Here, we focus on disintegrins, a class of low molecular mass
Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing, cysteine-rich polypeptide derived from various viper snake
venoms. This review describes the potential applications of disintegrins in field of integrin-related diseases,
especially arterial thrombosis, angiogenesis, tumor progression and septic inflammation. In addition, a novel
RGD-containing disintegrin TMV-7 is being developed as a safer antithrombotic agent with minimal side effects,
such as thrombocytopenia and bleeding.
Keywords: Snake venom proteins, Disintegrins, Antithrombotic agent, Arterial thrombosis, Angiogenesis, Septic
inflammation
Abbreviations: ADP, Adenosine diphosphate; ECM, Extracellular matrix; KGD, Lys-Gly-Asp; LIBs, Ligand-induced
binding sites; LPS, Lipopolysaccharide; mAb, Monoclonal antibody; PCI, Percutaneous coronary intervention;
PEG, Polyethylene glycol; PLA2, Phospholipase A2; PTCA, Percutaneous transluminal coronary angioplasty;
RGD, Arg-Gly-Asp; SVMP, Snake venom metalloproteinase; TLR, Toll-like receptor; vWF, von Willebrand factor
Background
Viperidae snake venoms profoundly affect blood coagu-
lation and platelet function. Ouyang et al. [1] classified
them into procoagulants, including factor X activator,
prothrombin activator, thrombin-like enzymes and platelet
aggregation inducer, and coagulation inhibitors, including
fibrinogenolytic enzymes, prothrombin activation inhibi-
tor, Factor X inhibitors, and platelet aggregation inhibitors.
This review will focus on the active components that
inhibit platelet function. Regarding platelet aggregation
inhibitors, many venom components including ADPase,
snake venom metalloproteinase (SVMP), phospholipase
A2, GPIb and IX binding proteins (i.e. snaclec) and disin-
tegrins have been reported to suppress platelet aggregation
in vitro. However, snaclecs and disintegrins affect in vivo
hemostasis and cell adhesion in a specific manner.
Snaclecs can either induce platelet aggregation through
vWF modulation, GPIb, α2β1, CLEC-2 and GPVI binding;
or inhibit platelet aggregation via GPIb blockade. The
biological activity of snaclecs has been reviewed com-
prehensively [2]. In the following, we will focus on
disintegrins and their potential applications.
Review
Role of integrins in thrombosis and hemostasis
Integrins, a family of non-covalently linked α/β heterodi-
meric cell adhesion receptors, play vital roles in platelet
aggregation, inflammatory reactions, cell adhesion, mi-
gration, angiogenesis and other biological processes [3].
Upon vascular injury, platelets adhere to the exposed
endothelium through the recognition of adhesive proteins
(i.e. vWF, collagen, fibronectin, laminin and fibrinogen) by
their respective platelet membrane receptors (i.e. GPIb,
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α2β1/GPVI, α5β1, α6β1 or αIIbβ3). Nowadays, α2β1/
GPVI are known to mediate collagen adhesion/activation
of platelets, whereas αIIbβ3 mediates the adhesion of fi-
brinogen, and the subsequent platelet-platelet aggregation,
a common final step of platelet aggregation shared all
stimulating agonists [4, 5]. Generally, the activation of
platelets consists of many signal transduction pathways
including PLA2/PLC activation and the rise of cytosolic
free Ca2+ after the ligation of agonist with its receptor,
leading to shape change, release reaction of ADP and
serotonin as well as thromboxane A2 formation, en-
hancement of procoagulation activity, and finally the
activation of αIIbβ3. The binding of plasma fibrinogen
to the activated αIIbβ3 bridges adjacent platelets and
lead to platelet aggregation which is reinforced by the
subsequent fibrin formation forming a hemostatic plug.
However, pathological thrombi may be formed due to
chronic endothelial injury in atherosclerotic patients [6].
Disintegrins as anti-thrombotic agents
Trigramin, a non-enzymatic small molecular weight poly-
peptide, was first discovered in 1987 [7]. Our earlier
studies showed that disintegrins derived from T. grami-
neus, Agkistrodon halys, and Agkistrodon rhodostoma
[8–10] inhibited platelet aggregation elicited by various
aggregation agonists including ADP, epinephrine, sodium
arachidonate, collagen and Ca2+ ionophone A23187 with
similar IC50 concentrations. They neither affect shape
change nor the cAMP level. Further studies showed that
trigramin and echistatin purified from T. gramineus
and Echis carinatus, inhibited fibrinogen binding to
ADP-stimulated platelets [7, 11]. 125I-trigramin showed
less than 5 % binding to ADP-stimulated platelets in
Glanzmann’s thrombasthenia patients (a genetic disease
with αIIbβ3-defect) compared to normal platelets,
suggesting that αIIbβ3 is the target of trigramin. In
addition, 7E3 mAb raised against αIIbβ3 and RGDS
inhibited 125I-trigramin binding. Subsequent sequen-
cing of trigramin showed that it is a RGD-containing
single polypeptide with 72 amino acid residues and six
disulfide bonds. Reduced trigramin lost its inhibitory
activity for platelet aggregation and binding capacity to
platelets, indicating that the biological activity of trigra-
min depends upon the presence of the RGD sequence
and its steric structure maintained by disulfide bridges
[7, 12]. Upon intravenous administration, trigramin
prolonged the bleeding time of severed mesentery
arteries, further supporting its in vivo antithrombotic
activity [13]. Later, other disintegrins, such as kistrin
and applagin were also shown to prevent experimental
thrombosis in dogs [14, 15]. Since then, many pharma-
ceutical companies have developed potential antithrom-
botic agents based on the structure of these disintegrins.
Among these disintegrins, barbourin, a KGD-containing
polypeptide, showed a higher specificity toward platelet
αIIβ3 than to endothelial αvβ3 [16]. Thus, eptifibatide
(Integrillin), a cyclic KGD-peptide, has been successfully
developed as an αIIbβ3 antagonist, used clinically for pre-
vention of restenosis during percutaneous transluminal
coronary angioplasty (PTCA) [17]. Tirofiban is also
designed to mimic the RGD-loop structure of the disin-
tegrin, echistatin [18]. In contrast to the first anti-
aggregation agent, the chimeric monoclonal c7E3Fab
(Abciximab, Reopro) a mAb raised against αIIbβ3 [19],
tirofiban and eptifibatide are small-mass αIIbβ3 antago-
nists derived from snake venom disintegrins. Vipegitide,
a folded KTS-containing peptidomimetic molecule, inhib-
ited the adhesion of α1/α2 integrin toward collagen, and
ADP and collagen-I induced platelet aggregation in
PRP and whole human blood [20], providing strategy
for developing α2β1 antagonists as antiplatelet agents.
Disintegrins as an anti-tumor and anti-angiogenesis
agents
Integrin αvβ3 modulates adhesion, migration and prolif-
eration of endothelial cells, smooth muscles, fibroblasts
and transformed cells, and thus plays crucial roles in
angiogenesis, restenosis, tumor cell migration and ath-
erosclerosis [21]. It has been reported that disintegrins
inhibit adhesion of tumor cells and endothelial cells to
extracellular matrix (ECM) through αvβ3 and α5β1.
Trigramin inhibited human melanoma cells adhesion
and spreading on fibronectin and fibrinogen [22], and
trifavin inhibited lung colonization of B16F10 melanoma
cells in an experimental model [23].
We previously reported that some disintegrins (accutin,
rhodostomin) dose-dependently inhibited the adhesion
of endothelial cells to ECM, cell proliferation, matrigel-
induced capillary tube formation, and neovasculariza-
tion in a chick chorioallantoic membrane (CAM) model,
mainly through αvβ3 blockade [24]. Accutin is the first
disintegrin reported to induce apoptosis of HUVECs [25].
Rhodostomin caused a higher percentage of cells at G2/M
phase, the cleavage of β-catenin, and poly (ADP-ribose)
polymerase during apoptosis [26]. Contortrostatin, a di-
meric disintegrin that binds to αvβ3, αvβ5 and/or α5β1,
was shown to inhibit the adhesion and invasion of tumor
cells and endothelial cells in vitro. In an orthotopic xeno-
graft model in nude mice, contortorstatin displayed good
anti-tumor and antiangiogenic potential against a breast
cancer cell line (MDA-MB-435) [27]. Vimocin and Vida-
pin, two synthetic peptides derived form KTS-containing
disintegrins obtustatin and viperistatin, were shown to in-
hibit angiogenesis induced by VEGF and glioma in CAM
assay, suggesting that they may serve as dual α1β1/α2β1
integrin antagonists in anti-angiogenesis and cancer
therapy [28]. Cilengitide, an RGD-containing pentapep-
tide and other αv integrin inhibitors have entered phase
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II/III clinical study as monotherapy for different tumor
types. However, Cilengitide did not alter the pattern of
glioblastoma progression [29], and in a phase III clinical
trial, the addition of Cilengitide to standard care did not
improve overall survival in patients with newly diagnosed
glioblastoma [30]. There are still some on-going phase I-II
clinical trials in combinative therapy for glioblastoma and
non-small-cell lung cancer [31, 32].
Disintegrins as anti-inflammatory agents
The innate immune system is the first line of defense
against microbial pathogens, protecting the host from
infection. In humans, Toll-like receptors (TLRs) specifically
recognize different microbial patterns to initiate signaling
pathways leading to inflammation [33]. TLR4 recognizes
lipopolysaccharide (LPS) -containing Gram negative
bacteria while TLR2 recognizes peptidoglycan of Gram
positive bacteria [34]. The β2 and β3 integrins regulate
leukocyte trafficking and function. Vitronectin and
αvβ3 have roles in initiating TLR2 responses to bacterial
lipopeptide [35]. Our recent studies showed that the dis-
integrin rhodostomin (Rn) possesses anti-inflammatory
activity mainly through blocking αvβ3-induced NFkB and
MAPK pathways, and MyD88-dependent TLRs (including
TLR2 and 4) in the production of cytokines in phagocytes.
Thus, Rn suppresses cytokine release, inhibits cell adhe-
sion and migration in vitro and even attenuates the acute
inflammatory activity in mice caused by bacterial infec-
tions [36, 37]. The activation of coagulation leading to
microvascular thrombi causes multiple organ failure and
correlates with mortality in severe sepsis [34]. Rn was also
shown to increase significantly the survival rate of septic
mice [36, 37]. The antiplatelet activity of Rn through
αIIbβ3 blockade may be partially responsible for its
capacity to reduce thrombi formation. The potential
application of rhodostomin as an inhibitor of TLR-2
and TLR-4 activation provides a promising lead for
drug development in infectious diseases induced by
complicated microbial patterns.
Novel αIIbβ3 antagonists derived from disintegrins
Although clinically available αIIbβ3 antagonists are highly
efficacious antithrombotics, their uses are currently
limited to percutaneous coronary intervention (PCI)
due to adverse reactions of thrombocytopenia and
bleeding. Increased bleeding risk prevents this class of
αIIbβ3 antagonists from being used at higher doses and
in patients at risk of bleeding [38]. It has been recog-
nized that binding of RGD-mimetic drugs including tir-
ofiban and eptifibatide to the RGD recognition site of
αIIbβ3 induces conformational changes and exposure
of αIIbβ3 neoepitopes (called ligand-induced binding
sites, LIBs) which are recognized by several murine
monoclonal antibodies [39]. As a consequence, patients
with preformed antibodies against LIBs may engage the
integrin β3 subunit such that FcγRII and its down-
stream signaling pathways become activated, resulting
in platelet clearance from circulation and concomitant
thrombocytopenia [40, 41]. Thus, it is crucial to
develop novel αIIbβ3 antagonists that do not cause
thrombocytopenia or bleeding. Recently RUC-1,2 and 4
compounds have been shown to be efficacious αIIbβ3
antagonist with minimal effect in altering the αIIbβ3
conformation [42, 43]. On the other hand, a membrane
permeable compound, mp6, was shown to inhibit the
outside-in signaling without affecting the fibrinogen-
αIIbβ3 ligation [44]. In our laboratory, we found a
unique RGD-containing disintegrin, TMV-7, purified
from T. macrosquamatus venom, which like RUC-2, had a
minimal priming effect in induction of fibrinogen-binding
or PAC-1 binding, reflecting that TMV-7 induces little
exposure of LIBs (unpublished data). It binds preferably to
αIIb, a binding epitope different from those of mAb 7E3,
tirofiban, eptifibatide and most RGD-containing disin-
tegrins including dimeric disintegrin, and short- and
medium-size disintegrins. TMV-7 has also been shown to
be an efficacious antithrombotic agent in FeCl3-induced
carotid artery injury, and irradiation-induced mesenteric
thrombosis models. At effective doses, TMV-7 did not
significantly prolong the bleeding time. Its unique mech-
anism of action may be related to inhibiting outside-in
signaling without affecting talin-mediated inside-out sig-
naling and clot retraction. Recent studies show that
Gα13 and talin play critical roles in thrombin-induced
integrin bidirectional signaling and bind to mutually ex-
clusive but distinct sites within integrin β3 cytoplasmic
domain in opposing waves, suggesting that targeting
outside-in signaling may prevent thrombosis without af-
fecting physiological hemostasis [45–47]. Therefore, the
elucidation of the structure-activity relationship between
TMV-7 and αIIbβ3 on a molecular level may provide
clues for drug development of an ideal antithrombotic
RGD-mimetic with a better safety profile.
Translational medicine derived from disintegrins
Over the last three decades, extensive researches on
RGD/KGD-containing disintegrins focused on their
interaction with platelet αIIbβ3 and endothelial or tumor
αvβ3, resulting in the successful development of the effi-
cacious αIIbβ3 antithrombotic agents such as tirofiban
and eptifibatide. However, the efforts for application of
αvβ3-specific RGD-mimetics in tumor therapy are still
going-on. The possible potential use of αvβ3 disintegrin
in septic inflammation is worthy of further investigation.
However, the possible antigenicity and brief half-life of in-
tact disintegrins in circulation limit their direct ultilization
as therapeutic agents although their molecular masses are
usually around 4000 ~ 7000 daltons. A alternative strategy
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in developing these disintegrins may be approached by
PEGylation or conjugation with human serum albumin
to minimize antigenicity or prolong their half-lives. A
PEGylated αIIbβ3 disintegrin (PEGylated rhodostomin)
has been reported to have an improved antithrombotic
activity [48]. PEGylated rhodostomin (PRn) has higher
antithrombotic potency and a longer half-life in vivo
compared with native rhodostomin. In addition, PRn
shows a better safety profile at an effective dose in vivo.
Therefore, PEGylation may be one ideal option in modi-
fying disintegrin derivatives to produce a safe thera-
peutic agent.
Conclusions
The discovery of the naturally occurring disintegrins has
inspired much research into the molecular interaction of
RGD/KGD disintegrins with integrin αIIbβ3, αvβ3 and
other integrins, leading to drug development of potential
agents in the fields of arterial thrombosis, angiogenesis,
tumor metastasis, inflammation and other integrin-
related diseases. With the aid of advanced molecular
biology techniques and the elucidation of physiological
and pathological roles of integrins, these disintegrins and
their mutants, targeting the binding site of the specific
integrin would be helpful for the further dissection of
their efficacy and adverse reactions mechanisms.
X-ray crystallography, ligand-receptor docking and
bioinformatics regarding the binding ligands (disintegrin
and mutants) toward integrins, and their atomic interac-
tions should accelerate the discovery of novel therapeutic
agents, especially the small-mass RGD-mimetics derived
from the naturally-occurring disintegrins.
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